國家衛生研究院 NHRI:Item 3990099045/10888
English  |  正體中文  |  简体中文  |  Items with full text/Total items : 12145/12927 (94%)
Visitors : 906643      Online Users : 928
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
Scope Tips:
  • please add "double quotation mark" for query phrases to get precise results
  • please goto advance search for comprehansive author search
    •  Adv. Search
    Home ‧ Login ‧ Upload ‧ Help ‧ About ‧ Administer Goto mobile version


    Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/10888


    Title: In silico-based identification of human alpha-enolase inhibitors to block cancer cell growth metabolically
    Authors: Lung, J;Chen, KL;Hung, CH;Chen, CC;Hung, MS;Lin, YC;Wu, CY;Lee, KD;Shih, NY;Tsai, YH
    Contributors: National Institute of Cancer Research
    Abstract: Unlimited growth of cancer cells requires an extensive nutrient supply. To meet this demand, cancer cells drastically upregulate glucose uptake and metabolism compared to normal cells. This difference has made the blocking of glycolysis a fascinating strategy to treat this malignant disease, alpha-enolase is not only one of the most upregulated glycolytic enzymes in cancer cells, but also associates with many cellular processes or conditions important to cancer cell survival, such as cell migration, invasion, and hypoxia. Targeting alpha-enolase could simultaneously disturb cancer cells in multiple ways and, therefore, is a good target for anticancer drug development. In the current study, more than 22 million chemical structures meeting the criteria of Lipinski's rule of five from the ZINC database were docked to alpha-enolase by virtual screening. Twenty-four chemical structures with docking scores better than that of the enolase substrate, 2-phosphoglyceratc, were further screened by the absorption, distribution, metabolism, excretion, and toxicity (ADMKT) properties prediction. Four of them were classified as non-mutagenic, non-carcinogenic, and capable of oral administration where they showed steady interactions to alpha-enolase that were comparable, even superior, to the currently available inhibitors in molecular dynamics (MD) simulation. These compounds may be considered promising leads for further development of the alpha-enolase inhibitors and could help fight cancer metabolically.
    Date: 2017-11-16
    Relation: Drug Design Development and Therapy. 2017 Nov 16;11:3281-3290.
    Link to: http://dx.doi.org/10.2147/dddt.s149214
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=1177-8881&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:000415381300002
    Cited Times(Scopus): https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85035193635
    Appears in Collections:[Neng-Yao Shih] Periodical Articles

    Files in This Item:

    File Description SizeFormat
    ISI000415381300002.pdf2984KbAdobe PDF232View/Open


    All items in NHRI are protected by copyright, with all rights reserved.

    Related Items in TAIR

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - Feedback